Literature DB >> 23921204

The management of head-and-neck paragangliomas.

Cristina Capatina1, Georgia Ntali, Niki Karavitaki, Ashley B Grossman.   

Abstract

Paragangliomas (PGLs) are tumours originating from neural crest-derived cells situated in the region of the autonomic nervous system ganglia. Head-and-neck PGLs (HNPGLs) originate from the sympathetic and parasympathetic paraganglia, most frequently from the carotid bodies and jugular, tympanic and vagal paraganglia, and are usually non-catecholamine secreting. Familial PGLs are considered to be rare, but recently genetic syndromes including multiple PGLs and/or phaeochromocytomas have been more thoroughly characterised. Nowadays, genetic screening for the genes frequently implicated in both familial and sporadic cases is routinely being recommended. HNPGLs are mostly benign, generally slow-growing tumours. Continuous growth leads to the involvement of adjacent neurovascular structures with increased morbidity rates and treatment-related complications. Optimal management mostly depends on tumour location, local involvement of neurovascular structures, estimated malignancy risk, patient age and general health. Surgery is the only treatment option offering the chance of cure but with significant morbidity rates, so a more conservative approach is usually considered, especially in the more difficult cases. Radiotherapy (fractionated or stereotactic radiosurgery) leads to tumour growth arrest and symptomatic improvement in the short term in many cases, but the long-term consequences are unclear. Early detection is essential in order to increase the chance of cure with a lower morbidity rate. The constant improvement in diagnostic imaging, surgical and radiation techniques has led to a safer management of these tumours, but there are still many therapeutic challenges, and no treatment algorithm has been agreed upon until now. The management of HNPGLs requires a multidisciplinary effort addressing the genetic, surgical, radiotherapeutic, oncological, neurological and endocrinological implications. Further progress in the understanding of their pathogenesis will lead to more effective screening and earlier diagnosis, both critical to successful treatment.

Entities:  

Keywords:  management; paragangliomas; radiotherapy; surgery; therapy

Mesh:

Year:  2013        PMID: 23921204     DOI: 10.1530/ERC-13-0223

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN: 1351-0088            Impact factor:   5.678


  16 in total

Review 1.  Current approaches and recent developments in the management of head and neck paragangliomas.

Authors:  David Taïeb; Alexandre Kaliski; Carsten C Boedeker; Victoria Martucci; Tito Fojo; John R Adler; Karel Pacak
Journal:  Endocr Rev       Date:  2014-07-17       Impact factor: 19.871

2.  Peptide receptor radionuclide therapy with (90)Y/ (177)Lu-labelled peptides for inoperable head and neck paragangliomas (glomus tumours).

Authors:  Ameya D Puranik; Harshad R Kulkarni; Aviral Singh; Richard P Baum
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-03-31       Impact factor: 9.236

3.  Update from the 4th Edition of the World Health Organization Classification of Head and Neck Tumours: Paragangliomas.

Authors:  Michelle D Williams; Arthur S Tischler
Journal:  Head Neck Pathol       Date:  2017-02-28

4.  Some Considerations in Treating Malignant Head and Neck Paragangliomas.

Authors:  Abhishek Jha; Naris Nilubol; Karel Pacak
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2020-02-01       Impact factor: 6.223

Review 5.  Paragangliomas of the Head and Neck: An Overview from Diagnosis to Genetics.

Authors:  Michelle D Williams
Journal:  Head Neck Pathol       Date:  2017-03-20

6.  Krebs cycle metabolite profiling for identification and stratification of pheochromocytomas/paragangliomas due to succinate dehydrogenase deficiency.

Authors:  Susan Richter; Mirko Peitzsch; Elena Rapizzi; Jacques W Lenders; Nan Qin; Aguirre A de Cubas; Francesca Schiavi; Jyotsna U Rao; Felix Beuschlein; Marcus Quinkler; Henri J Timmers; Giuseppe Opocher; Massimo Mannelli; Karel Pacak; Mercedes Robledo; Graeme Eisenhofer
Journal:  J Clin Endocrinol Metab       Date:  2014-07-11       Impact factor: 5.958

7.  Role of 68Ga-DOTATATE PET/CT in a Case of SDHB-Related Pterygopalatine Fossa Paraganglioma Successfully Controlled with Octreotide.

Authors:  Abhishek Jha; Mayank Patel; Eva Baker; Melissa K Gonzales; Alexander Ling; Corina Millo; Marianne Knue; Ali Cahid Civelek; Karel Pacak
Journal:  Nucl Med Mol Imaging       Date:  2020-01-22

8.  Catecholamine-secreting paraganglioma: the challenges of perioperative management.

Authors:  Eamon Shamil; Liam Brennan; Piyush Jani
Journal:  BMJ Case Rep       Date:  2015-11-03

Review 9.  [Head and neck paragangliomas: An interdisciplinary challenge].

Authors:  J Künzel; K Bahr; M Hainz; H Rossmann; C Matthias
Journal:  HNO       Date:  2015-12       Impact factor: 1.284

10.  Evaluation of Head and Neck Paragangliomas by Computed Tomography in Patients with Pheochromocytoma-Paraganglioma Syndromes.

Authors:  Ilona Michałowska; Anna Lewczuk; Jarosław Ćwikła; Aleksander Prejbisz; Urszula Swoboda-Rydz; Mariusz I Furmanek; Małgorzata Szperl; Andrzej Januszewicz; Mariola Pęczkowska
Journal:  Pol J Radiol       Date:  2016-10-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.